Medical

Nasus Pharma has announced the initiation of a Phase 1 PK study of its NS003 nasal powder ondansetron, which the company is developing for the treatment of nausea and vomiting following surgical procedures or chemotherapy.… Read more . . .

California-based startup Mosanna Therapeutics, which raised $80 million last year for clinical development of MOS118 nasal spray for the treatment of obstructive sleep apnea, said that results from a Phase 1 study support progression into… Read more . . .

Tiziana Life Sciences has announced the initiation of the Phase 2a Healey ALS MyMatch BANYAN trial of intranasal foralumab in people with amyotrophic lateral sclerosis. The company announced in November 2024 the ALS Association would… Read more . . .

Kither Biotech has announced the initiation of a Phase 1b /2a study of KIT2014 inhaled PDE3/4 inhibitor in patients with COPD. The company recently announced results from a Phase 1 trial of KIT2014 in healthy… Read more . . .

Chinese OINDP developer CF Pharmtech has announced the initiation of its Phase 1 trial of its ICF004 dry powder inhaler, which the company is developing for the treatment of fibrotic lung diseases. The study record… Read more . . .

Polyrizon has announced the initiation of its first clinical trial, a study of its Nasarix (PL-14) hydrogel nasal spray in patients with seasonal allergic rhinitis. In September 2025, the company said that it had submitted… Read more . . .

SpliSense announced that it has initiated the Phase 2b portion of the SPL84-02 trial of the SPL84 inhaled antisense oligonucleotide in CF patients with the 3849+10kb C→T splicing mutation in the CFTR gene. The Phase… Read more . . .

Agomab Therapeutics has announced that the final part of a Phase 1 study of its AGMB-447 inhaled ALK5 inhibitor, which enrolled patients with idiopathic pulmonary fibrosis, demonstrated “a generally favorable safety and tolerability profile” in… Read more . . .

Pulmovant has announced that the Phase 2 PHocus clinical trial of its inhaled dry powder mosliciguat in patients with pulmonary hypertension due to interstitial lung disease (PH-ILD) met its primary endpoint, demonstrating a significant reduction in… Read more . . .